

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10663471/publications.pdf>

Version: 2024-02-01

87  
papers

6,580  
citations

117625

34  
h-index

62596

80  
g-index

89  
all docs

89  
docs citations

89  
times ranked

7138  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dopamine Receptors: From Structure to Function. <i>Physiological Reviews</i> , 1998, 78, 189-225.	28.8	3,059
2	Regulation of Dopamine D1 Receptor Trafficking and Desensitization by Oligomerization with Glutamate N-Methyl-D-aspartate Receptors. <i>Journal of Biological Chemistry</i> , 2003, 278, 20196-20202.	3.4	200
3	Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization. <i>Molecular Pharmacology</i> , 2008, 74, 59-69.	2.3	195
4	Anterior Pituitary Hypoplasia and Dwarfism in Mice Lacking the Dopamine Transporter. <i>Neuron</i> , 1997, 19, 127-138.	8.1	192
5	Induction of the unfolded protein response by $\alpha$ -synuclein in experimental models of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2011, 116, 588-605.	3.9	178
6	Review: Parkinson's disease: from synaptic loss to connectome dysfunction. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 77-94.	3.2	163
7	Dopamine Uptake is Differentially Regulated in Rat Striatum and Nucleus Accumbens. <i>Journal of Neurochemistry</i> , 1985, 45, 51-56.	3.9	132
8	$\alpha$ -synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. <i>Journal of Cell Science</i> , 2015, 128, 2231-2243.	2.0	99
9	From $\alpha$ -synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease. <i>Brain Research</i> , 2012, 1476, 183-202.	2.2	89
10	D2 dopamine receptors associated with inhibition of dopamine release from rat neostriatum are independent of cyclic AMP. <i>Neuroscience Letters</i> , 1986, 71, 192-196.	2.1	79
11	Loss of Synaptic D1 Dopamine/N-Methyl-d-aspartate Glutamate Receptor Complexes in L-DOPA-Induced Dyskinesia in the Rat. <i>Molecular Pharmacology</i> , 2006, 69, 805-812.	2.3	75
12	$\alpha$ -synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D <sub>2</sub> /D <sub>3</sub> receptor activation. <i>Journal of Neurochemistry</i> , 2008, 106, 560-577.	3.9	74
13	The NMDA/D1 Receptor Complex as a New Target in Drug Development. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 801-808.	2.1	72
14	The Contribution of $\alpha$ -Synuclein Spreading to Parkinson's Disease Synaptopathy. <i>Neural Plasticity</i> , 2017, 2017, 1-15.	2.2	70
15	Nerve Growth Factor Regulates Dopamine D2 Receptor Expression in Prolactinoma Cell Lines via p75NGFR-Mediated Activation of Nuclear Factor- $\kappa$ B. <i>Molecular Endocrinology</i> , 2002, 16, 353-366.	3.7	66
16	L- $\alpha$ -glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. <i>European Journal of Pharmacology</i> , 1992, 211, 351-358.	3.5	65
17	Redistribution of DAT/ $\alpha$ -Synuclein Complexes Visualized by <i>in Situ</i> Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease. <i>PLoS ONE</i> , 2011, 6, e27959.	2.5	62
18	Mitochondrial Dysfunction and $\alpha$ -Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First?. <i>Parkinson's Disease</i> , 2015, 2015, 1-10.	1.1	62

#	ARTICLE	IF	CITATIONS
19	Epidermal Growth Factor Induces the Functional Expression of Dopamine Receptors in the GH3 Cell Line*. <i>Endocrinology</i> , 1991, 128, 13-20.	2.8	61
20	Nicotine-Induced Structural Plasticity in Mesencephalic Dopaminergic Neurons Is Mediated by Dopamine D3 Receptors and Akt-mTORC1 Signaling. <i>Molecular Pharmacology</i> , 2013, 83, 1176-1189.	2.3	61
21	GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. <i>Experimental Cell Research</i> , 2014, 323, 100-111.	2.6	61
22	Repeated reserpine administration up-regulates the transduction mechanisms of D1 receptors without changing the density of [3H]SCH 23390 binding. <i>Brain Research</i> , 1989, 483, 117-122.	2.2	58
23	Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function. <i>Current Opinion in Pharmacology</i> , 2010, 10, 87-92.	3.5	58
24	Nuclear Factor- $\kappa$ B Dysregulation and $\alpha$ -Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 68.	3.4	56
25	Synapsin III deficiency hampers $\alpha$ -synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease. <i>Acta Neuropathologica</i> , 2018, 136, 621-639.	7.7	53
26	Characterization of Dopamine Receptors Associated with Aldosterone Secretion in Rat Adrenal Glomerulosa*. <i>Endocrinology</i> , 1986, 119, 2227-2232.	2.8	48
27	Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. <i>European Journal of Neuroscience</i> , 2008, 28, 1231-1240.	2.6	48
28	Identification and Characterization of Postsynaptic D1- and D2-Dopamine Receptors in the Cardiovascular System. <i>Journal of Cardiovascular Pharmacology</i> , 1988, 11, 643-650.	1.9	45
29	Identification and Characterization of Two Nuclear Factor- $\kappa$ B Sites in the Regulatory Region of the Dopamine D2 Receptor. <i>Endocrinology</i> , 2007, 148, 2563-2570.	2.8	43
30	Pre-synaptic dopamine D <sub>3</sub> receptor mediates cocaine-induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways. <i>Journal of Neurochemistry</i> , 2012, 120, 765-778.	3.9	43
31	Repeated administration of ( $\alpha$ ) sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic brain regions. <i>European Journal of Pharmacology</i> , 1987, 138, 45-51.	3.5	39
32	Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. <i>Brain Research</i> , 2012, 1432, 95-113.	2.2	39
33	Synapsin III is a key component of $\alpha$ -synuclein fibrils in Lewy bodies of PD brains. <i>Brain Pathology</i> , 2018, 28, 875-888.	4.1	37
34	The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. <i>Journal of Receptor and Signal Transduction Research</i> , 2010, 30, 347-354.	2.5	36
35	The D3 dopamine receptor: From structural interactions to function. <i>European Neuropsychopharmacology</i> , 2015, 25, 1462-1469.	0.7	35
36	The $\alpha$ -Proximity Ligation Assay to Probe Protein-Protein Interactions in Intact Tissues. <i>Methods in Molecular Biology</i> , 2014, 1174, 397-405.	0.9	35

#	ARTICLE	IF	CITATIONS
37	Nerve Growth Factor in Pituitary Development and Pituitary Tumors. <i>Frontiers in Neuroendocrinology</i> , 1998, 19, 128-150.	5.2	34
38	Nerve growth factor signaling in prostate health and disease. <i>Growth Factors</i> , 2010, 28, 191-201.	1.7	33
39	Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2013, 54, 339-348.	4.4	33
40	Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4594-4602.	3.6	31
41	Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. II. Dorsal hippocampus. <i>Neuroscience Letters</i> , 1988, 87, 253-258.	2.1	30
42	Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure. <i>Neurochemistry International</i> , 2015, 85-86, 14-23.	3.8	30
43	Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. <i>Molecular Neurobiology</i> , 2018, 55, 1054-1067.	4.0	30
44	Palbociclib inhibits proliferation of human adrenocortical tumor cells. <i>Endocrine</i> , 2018, 59, 213-217.	2.3	28
45	Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection. <i>Biomolecules</i> , 2020, 10, 1016.	4.0	28
46	Dopamine D3 and acetylcholine nicotinic receptor heteromerization in midbrain dopamine neurons: Relevance for neuroplasticity. <i>European Neuropsychopharmacology</i> , 2017, 27, 313-324.	0.7	27
47	The tyrosine phosphatase Shpâ€² interacts with the dopamine D<sub>1</sub> receptor and triggers D<sub>1</sub>-mediated Erk signaling in striatal neurons. <i>Journal of Neurochemistry</i> , 2011, 117, 253-263.	3.9	25
48	Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer. <i>Neurobiology of Disease</i> , 2019, 129, 1-12.	4.4	25
49	Evidence for the presence of D1 and D2 dopamine receptors in the rat adrenal cortex. <i>European Journal of Pharmacology</i> , 1985, 109, 315-316.	3.5	23
50	Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145. <i>European Journal of Endocrinology</i> , 2002, 147, 407-415.	3.7	22
51	In vitro antitumor activity of progesterone in human adrenocortical carcinoma. <i>Endocrine</i> , 2019, 63, 592-601.	2.3	21
52	Role of receptor heterodimers in the development of l-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, S159-S164.	2.2	20
53	Dopamine Transporter/Î±-Synuclein Complexes Are Altered in the Post Mortem Caudate Putamen of Parkinsonâ€™s Disease: An In Situ Proximity Ligation Assay Study. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1611.	4.1	20
54	Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate. <i>Neurobiology of Disease</i> , 2020, 138, 104789.	4.4	19

#	ARTICLE	IF	CITATIONS
55	Nerve Growth Factor Restores p53 Function in Pituitary Tumor Cell Lines via trkA-Mediated Activation of Phosphatidylinositol 3-Kinase. <i>Molecular Endocrinology</i> , 2004, 18, 162-172.	3.7	18
56	Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. I. Frontal cortex. <i>Neuroscience Letters</i> , 1988, 87, 247-252.	2.1	17
57	The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease. <i>Experimental Neurology</i> , 2017, 291, 1-7.	4.1	17
58	Identification of D-2 dopaminergic receptors in bovine adrenal cortex. <i>Life Sciences</i> , 1985, 37, 2539-2548.	4.3	15
59	Dopaminergic Regulation of Aldosterone Secretion. <i>American Journal of Hypertension</i> , 1990, 3, 93S-95S.	2.0	15
60	Growth factors in pituitary tumors. <i>Pituitary</i> , 1999, 1, 153-158.	2.9	15
61	Low doses of l-sulpiride down-regulate striatal and cortical dopamine receptors and $\beta^2$ -adrenoceptors. <i>European Journal of Pharmacology</i> , 1991, 199, 247-253.	3.5	14
62	Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: Role of P/Q-type high voltage activated Ca <sup>++</sup> channels and endogenous dopamine. <i>Molecular and Cellular Neurosciences</i> , 2006, 31, 284-292.	2.2	14
63	Shp $\epsilon$ 2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 512-520.	3.9	14
64	The novel hybrid agonist HyNDA-1 targets the D3R-nAChR heteromeric complex in dopaminergic neurons. <i>Biochemical Pharmacology</i> , 2019, 163, 154-168.	4.4	14
65	Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation. <i>Neurobiology of Aging</i> , 2021, 99, 65-78.	3.1	14
66	Striatal adenylate cyclase-inhibiting dopamine D2 receptors are not affected by the aging process. <i>Neuroscience Letters</i> , 1987, 75, 38-42.	2.1	13
67	Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation. <i>European Journal of Endocrinology</i> , 2002, 147, 371-379.	3.7	12
68	Bifunctional compounds targeting both D2 and non- $\beta_7$ nACh receptors: Design, synthesis and pharmacological characterization. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 367-383.	5.5	12
69	Repeated administration of lisuride down-regulates dopamine D-2 receptor function in mesostriatal and in mesolimbocortical rat brain regions. <i>European Journal of Pharmacology</i> , 1990, 176, 85-90.	3.5	11
70	Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 164-175.	2.5	11
71	Evidence for the presence of both D-1 and D-2 dopamine receptors in human esophagus. <i>Life Sciences</i> , 1990, 47, 447-455.	4.3	10
72	Opposing roles for D-1 and D-2 dopamine receptors in the regulation of lower esophageal sphincter motility in the rat. <i>Life Sciences</i> , 1994, 54, 1035-1045.	4.3	10

#	ARTICLE	IF	CITATIONS
73	Epidermal Growth Factor Promotes Uncoupling from Adenylyl Cyclase of the Rat D <sub>2S</sub> Receptor Expressed in GH4C1 Cells. <i>Journal of Neurochemistry</i> , 1994, 62, 907-915.	3.9	10
74	Differential effect of acute reserpine administration on D-1 and D-2 dopaminergic receptor density and function in rat striatum. <i>Neurochemistry International</i> , 1989, 14, 61-64.	3.8	9
75	Increased serum concentration of nerve growth factor in patients with microprolactinoma. <i>Neuropeptides</i> , 2004, 38, 21-24.	2.2	7
76	Dopaminergic Receptor Mechanisms Modulating the Renin-Angiotensin System and Aldosterone Secretion. <i>Journal of Cardiovascular Pharmacology</i> , 1989, 14, S29-S39.	1.9	6
77	Differential gene expression of dopamine D-2 receptor subtypes in rat chromaffin cells and sympathetic neurons in culture. <i>NeuroReport</i> , 2000, 11, 2467-2471.	1.2	6
78	Molecular and pharmacological detection of dopaminergic receptors in the human male urinary tract. <i>Neurourology and Urodynamics</i> , 2009, 28, 343-348.	1.5	6
79	Growth factors in the pathogenesis of prolactin-secreting tumors. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 402-411.	3.3	5
80	Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of c-Fos and p70S6K Signaling Pathway. <i>Molecular Neurobiology</i> , 2022, 59, 2129-2149.	4.0	5
81	Nerve growth factor, D2 receptor isoforms, and pituitary tumors. <i>Endocrine</i> , 2012, 42, 466-467.	2.3	4
82	Induced pluripotent stem cells for defining Parkinsonian patient subtypes: a further step toward precision medicine. <i>Neural Regeneration Research</i> , 2022, 17, 767.	3.0	4
83	Establishment and characterization of induced pluripotent stem cell (iPSCs) line UNIBSi014-A from a healthy female donor. <i>Stem Cell Research</i> , 2021, 51, 102216.	0.7	2
84	Effects of chronic treatment with L-alpha-glycerylphosphorylcholine on hippocampal cholinergic transmission in the rat. <i>Drug Development Research</i> , 1992, 27, 277-286.	2.9	1
85	Generation of two human induced pluripotent stem cell lines, UNIBSi012-A and UNIBSi013-A, from two patients with treatment-resistant depression. <i>Stem Cell Research</i> , 2020, 49, 102104.	0.7	1
86	Recent Advances in Dopamine D3 Receptor Heterodimers: Focus on Dopamine D3 and D1 Receptor Receptor Interaction and Striatal Function. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 1.	1.7	1
87	Oligomerization of Dopamine D1 and Glutamate NMDA Receptors: A New Mechanism Regulating Striatal Function. , 2005, , 141-149.		0